{"id":"NCT01578499","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)","officialTitle":"A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-11","primaryCompletion":"2016-05-31","completion":"2018-07-06","firstPosted":"2012-04-17","resultsPosted":"2018-03-16","lastUpdate":"2021-01-05"},"enrollment":131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Cutaneous Anaplastic Large Cell Lymphoma","Mycosis Fungoides","Cutaneous T-Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Brentuximab Vedotin","otherNames":["SGN-35"]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Bexarotene","otherNames":[]}],"arms":[{"label":"Brentuximab vedotin","type":"EXPERIMENTAL"},{"label":"Methotrexate or Bexarotene","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma \\[mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) \\]compared to that achieved with therapy in the control arm.","primaryOutcome":{"measure":"Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)","timeFrame":"Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)","effectByArm":[{"arm":"Brentuximab Vedotin","deltaMin":54.7,"sd":null},{"arm":"Methotrexate or Bexarotene","deltaMin":12.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":41,"countries":["United States","Australia","Austria","Belgium","Brazil","France","Germany","Italy","Poland","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["34507350","33794441","32632956","32502876","28600132"],"seeAlso":["https://www.alcanzaclinicaltrial.com/"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":66},"commonTop":["Fatigue","Nausea","Peripheral sensory neuropathy","Diarrhoea","Pruritus"]}}